MyStocks

MEMBER'S LOGINX

Remember Username
Keep me signed in

(Please do not use this option on a public machine)

Home
Research It
SUVEN LIFE SCIENCES LTD. (pharmaceuticals)
SUVEN LIFE SCIENCES LTD. Financial Data

SUVEN LIFE Fact Sheet (SVNP)

Mail
Print
FaceBook
Twitter
Linked In
WhatsApp

Watch Now: The Instant Income Summit

Here is the latest financial fact sheet of SUVEN LIFE. For more details, see the SUVEN LIFE quarterly results and SUVEN LIFE share price and chart. For a sector overview, read our pharmaceuticals sector report.

SUVEN LIFESCIENCES Price History

Price	Rs	38.3
Mkt Cap	Rs m	4,875
Vol	'000	32.2
P/E	X	4.0
P/CF	X	4.5
EPS (TTM)	Rs	9.6

% ch	%	-1.9
No. of shares	m	127.28
% ch week	%	-5.2
% ch 1-mth	%	11.8
% ch 12-mth	%	-84.8
52 week H/L	Rs	334.9/19.4

(As on Jul 10, 2020 (Close))

» Best Performing pharmaceuticals Stocks

1d 1w 1m 3m 6m 1y 3y 5y Max

* Results Consolidated

EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

SUVEN LIFESCIENCES Financials

No. of Mths Year Ending	12 Mar-15	12 Mar-16	12 Mar-17	12 Mar-18	12 Mar-19	5-Yr Chart Click to enlarge

SUVEN LIFESCIENCES EQUITY SHARE DATA
High	Rs	323	339	229	251	338
Low	Rs	72	144	151	155	169
Sales per share (Unadj.)	Rs	40.9	39.2	42.7	49.1	52.1
Earnings per share (Unadj.)	Rs	8.5	5.6	6.9	9.7	6.8
Diluted earnings per share	Rs	8.5	5.6	6.8	9.7	6.8
Cash flow per share (Unadj.)	Rs	9.5	7.0	8.5	11.4	8.6
Dividends per share (Unadj.)	Rs	0.60	2.00	1.00	1.50	1.50
Adj. dividends per share	Rs	0.60	2.00	1.00	1.50	1.50
Dividend yield (eoy)	%	0.3	0.8	0.5	0.7	0.6
Book value per share (Unadj.)	Rs	44.3	46.8	52.4	60.3	65.3
Adj. book value per share	Rs	44.3	46.8	52.4	60.3	65.3
Shares outstanding (eoy)	m	127.28	127.28	127.28	127.28	127.28
Bonus/Rights/Conversions		IS	-	-	-	-
Price / Sales ratio	x	4.8	6.2	4.4	4.1	4.9
Avg P/E ratio	x	23.1	42.8	27.7	20.9	37.1
P/CF ratio (eoy)	x	20.8	34.4	22.2	17.8	29.6
Price / Book Value ratio	x	4.5	5.2	3.6	3.4	3.9
Dividend payout	%	7.0	35.4	14.6	15.4	22.0
Avg Mkt Cap	Rs m	25,100	30,732	24,158	25,825	32,272
No. of employees	`000	0.9	1.0	1.0	1.1	1.1
Total wages/salary	Rs m	365	409	522	613	661
Avg. sales/employee	Rs Th	5,912.1	5,236.1	5,349.7	5,832.6	6,132.2
Avg. wages/employee	Rs Th	414.4	429.1	513.5	571.5	611.1
Avg. net profit/employee	Rs Th	1,234.4	753.0	858.1	1,153.8	803.5

SUVEN LIFESCIENCES INCOME DATA
Net Sales	Rs m	5,209	4,995	5,435	6,253	6,635
Other income	Rs m	86	194	211	233	242
Total revenues	Rs m	5,294	5,189	5,646	6,485	6,877
Gross profit	Rs m	1,595	1,016	1,291	1,982	1,604
Depreciation	Rs m	118	175	214	213	221
Interest	Rs m	47	59	57	46	38
Profit before tax	Rs m	1,516	976	1,231	1,955	1,587
Minority Interest	Rs m	0	0	0	0	0
Prior Period Items	Rs m	0	0	0	0	0
Extraordinary Inc (Exp)	Rs m	0	0	0	0	0
Tax	Rs m	428	257	359	718	718
Profit after tax	Rs m	1,088	718	872	1,237	869
Gross profit margin	%	30.6	20.3	23.7	31.7	24.2
Effective tax rate	%	28.2	26.4	29.2	36.7	45.2
Net profit margin	%	20.9	14.4	16.0	19.8	13.1

SUVEN LIFESCIENCES BALANCE SHEET DATA
Current assets	Rs m	4,494	4,277	4,917	5,696	6,232
Current liabilities	Rs m	1,185	1,107	1,186	1,216	1,490
Net working cap to sales	%	63.5	63.5	68.6	71.6	71.5
Current ratio	x	3.8	3.9	4.1	4.7	4.2
Inventory Days	Days	57	61	62	81	86
Debtors Days	Days	28	39	31	36	83
Net fixed assets	Rs m	2,790	3,126	3,154	3,325	4,043
Share capital	Rs m	127	127	127	127	127
"Free" reserves	Rs m	5,510	5,826	6,543	7,547	8,183
Net worth	Rs m	5,637	5,953	6,670	7,674	8,310
Long term debt	Rs m	594	416	259	22	18
Total assets	Rs m	7,456	7,515	8,157	9,192	10,389
Interest coverage	x	33.2	17.6	22.7	43.2	43.1
Debt to equity ratio	x	0.1	0.1	0	0	0
Sales to assets ratio	x	0.7	0.7	0.7	0.7	0.6
Return on assets	%	15.2	10.3	11.4	14.0	8.7
Return on equity	%	19.3	12.1	13.1	16.1	10.5
Return on capital	%	25.1	16.2	18.6	26.0	19.5
Exports to sales	%	88.1	87.5	0	0	0
Imports to sales	%	11.6	12.2	0	0	0
Exports (fob)	Rs m	4,590	4,371	0	0	0
Imports (cif)	Rs m	602	611	0	0	0
Fx inflow	Rs m	4,779	4,666	4,943	5,066	5,622
Fx outflow	Rs m	855	942	1,857	2,001	1,799
Net fx	Rs m	3,924	3,724	3,086	3,065	3,822

SUVEN LIFESCIENCES CASH FLOW
From Operations	Rs m	1,429	675	1,092	699	356
From Investments	Rs m	-1,105	-386	-3,107	-6	-279
From Financial Activity	Rs m	1,791	-681	-304	-521	-225
Net Cashflow	Rs m	2,116	-392	-2,319	173	-148

* Results Consolidated

Source: Company Annual Reports, Regulatory Filings, Equitymaster

» Historical quarterly results for suven life sciences ltd.

Share Holding

Indian Promoters	63.4%
Foreign collaborators	0.0%
Indian inst/Mut Fund	0.0%
FIIs	0.0%
ADR/GDR	0.0%
Free float	36.5%
Shareholders	37,287
Pledged promoter(s) holding	0.0%

Today's Market

Sensex Ends 143 Points Lower; Banking and Finance Stocks Witness Selling(Closing)

Indian share markets witnessed selling pressure throughout the day today, tracking weak global cues as coronavirus cases continue to surge across the world.

Views on news

SUVEN LIFESCIENCES Announces Quarterly Results (1QFY20); Net Profit Up 47.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 572 m (up 47.2% YoY). Sales on the other hand came in at Rs 2 bn (up 3.8% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

SUVEN LIFESCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 22, 2019 | Updated on Jul 22, 2019

Here's an analysis of the annual report of SUVEN LIFESCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUVEN LIFESCIENCES. Also includes updates on the valuation of SUVEN LIFESCIENCES.

SUVEN LIFESCIENCES Announces Quarterly Results (4QFY19); Net Profit Up 8.7% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 680 m (up 8.7% YoY). Sales on the other hand came in at Rs 3 bn (up 18.5% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

SUVEN LIFE 2017-18 Annual Report Analysis (Annual Result Update)

Aug 14, 2018 | Updated on Aug 14, 2018

Here's an analysis of the annual report of SUVEN LIFE for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUVEN LIFE. Also includes updates on the valuation of SUVEN LIFE.

More Views on News

TRACK SUVEN LIFESCIENCES

Track your investment in SUVEN LIFESCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
Add To MyStocks

SUVEN LIFESCIENCES 8-QTR ANALYSIS

Detailed Quarterly Results With Charts

COMPARE SUVEN LIFESCIENCES WITH

FEATURED VIDEOS

What No One Told You About Finding the Best Penny Stocks

Using Price Action to Identify Trading Opportunity in Defense Stocks

Three Charts on One of the Quickest Bull Markets in History

This is Where You Will Find the Most Promising Bets for Post Covid Rebound

Here's How You Can Make Big Money from Penny Stocks

MARKET STATS

ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

FREE NEWSLETTERS

PREMIUM PRODUCTS

QUICK LINKS

APPS

FOLLOW

Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.